Heritas-backed Holmusk announces US$21.5 million series A financing led by Optum Ventures and Health Catalyst Capital
Holmusk, a leading data science and health technology company, today announced the closing of US$21.5m Series A financing. The round was led by Optum Ventures, the venture arm of UnitedHealth Group, and Health Catalyst Capital.
According to company’s press release the new funding round will allow Holmusk to expand its US operations in New York City, as well as to continue investing in its proprietary technology to build the world’s largest Real-World Evidence (RWE) platform in behavioral health and chronic diseases. This will enable the company to harness and analyze real-world data to accelerate drug development and data-driven medicine, and provide evidence-based care that healthcare providers, payers and patients can use for fully informed care and better treatment decisions.
Heritas Capital, which led the US$9.75m Pre-Series A round announced in 2018, also followed on in the current round through its Heritas Venture Fund.
“We congratulate the Holmusk team on the successful Series A fundraise,” said Chik Wai Chiew, CEO and Executive Director of Heritas Capital Management. “We are pleased to continue backing Holmusk alongside quality investors like Optum Ventures and Health Catalyst Capital for the next phase of growth within Asia as well as globally to address unmet needs in behavioral health disorders and chronic diseases.”